Patents Assigned to Wistar Institute of Anatomy and Biology
-
Publication number: 20220113311Abstract: Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.Type: ApplicationFiled: December 23, 2021Publication date: April 14, 2022Applicant: The Wistar Institute of Anatomy and BiologyInventor: Dario C. Altieri, I
-
Patent number: 11248033Abstract: A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSH? sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided.Type: GrantFiled: February 21, 2019Date of Patent: February 15, 2022Assignee: The Wistar Institute of Anatomy and BiologyInventors: Alfredo Perales-Puchalt, Jose R. Conejo-Garcia
-
Patent number: 11242317Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.Type: GrantFiled: July 23, 2019Date of Patent: February 8, 2022Assignee: The Wistar Institute of Anatomy and BiologyInventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
-
Patent number: 11230592Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.Type: GrantFiled: September 27, 2018Date of Patent: January 25, 2022Assignees: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, INOVIO PHARMACEUTICALS, INC.Inventors: David Weiner, Trevor R F Smith, Kar Muthumani
-
Publication number: 20220002291Abstract: The present disclosure provides compounds of the formula (I) wherein these compounds contain a ligand which binds to one or more target proteins such as CDK4 or CDK6 and a ligand which binds to the machinery associated with the ubiquitinating protein machinery. Also provided herein are methods of using these compounds in compositions or methods of treating patients with these compounds for the treatment of a disease or disorders such as cancer.Type: ApplicationFiled: October 30, 2019Publication date: January 6, 2022Applicants: The Wistar Institute of Anatomy and Biology, Thomas Jefferson UniversityInventors: Joseph SALVINO, Bruno CALABRETTA, Marco DE DOMINICI, You Cai XIAO
-
Patent number: 11208468Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.Type: GrantFiled: February 16, 2017Date of Patent: December 28, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
-
Patent number: 11208478Abstract: Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.Type: GrantFiled: August 4, 2017Date of Patent: December 28, 2021Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventor: Dario C. Altieri
-
Patent number: 11207402Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.Type: GrantFiled: May 10, 2019Date of Patent: December 28, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Hildegund C. J. Ertl, Marcio O. Lasaro, Luis C. S. Ferreira
-
Patent number: 11149072Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: GrantFiled: August 23, 2019Date of Patent: October 19, 2021Assignees: H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
-
Publication number: 20210251987Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer arc disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.Type: ApplicationFiled: April 26, 2021Publication date: August 19, 2021Applicant: The Wistar Institute of Anatomy and BiologyInventors: Rugang Zhang, Sergey Karakashev
-
Patent number: 11091518Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.Type: GrantFiled: May 5, 2017Date of Patent: August 17, 2021Assignees: The Trustees of the University of Pennsylvania, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Ami Patel, Jian Yan
-
Patent number: 11073521Abstract: A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.Type: GrantFiled: May 31, 2016Date of Patent: July 27, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Dmitry I. Gabrilovich, Thomas C. Condamine
-
Patent number: 11033541Abstract: Methods and compositions are described for enhancing tissue regeneration or wound repair in a mammalian subject comprising a composition comprising (a) a proline hydroxylase inhibitor component or molecule that increases or upregulates HIF1a and (b) a carrier component comprising a hydrogel.Type: GrantFiled: June 3, 2019Date of Patent: June 15, 2021Assignees: Northwestern University, The Wistar Institute of Anatomy and BiologyInventors: Phillip B. Messersmith, Iossif A. Strehin, Ellen Heber-Katz
-
Patent number: 10987353Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.Type: GrantFiled: April 24, 2017Date of Patent: April 27, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Rugang Zhang, Sergey Karakashev
-
Publication number: 20210113602Abstract: Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there are no clinical agents available to effectively target NRAS or any other RAS oncogene. An alternative approach is to identify and target critical tumor vulnerabilities or non-oncogene addictions that are essential for tumor survival. The inventors investigated the consequences of NRAS blockade in NRAS-mutant melanoma and show that decreased expression of the telomerase catalytic subunit, TERT, is a major consequence. TERT silencing or treatment of NRAS-mutant melanoma with the telomerase-dependent telomere uncapping agent 6-thio-2?-deoxy-guanosine (6-thio-dG), led to rapid cell death, along with evidence of both telomeric and non-telomeric DNA damage, increased ROS levels, and upregulation of a mitochondrial anti-oxidant adaptive response.Type: ApplicationFiled: February 28, 2019Publication date: April 22, 2021Applicants: The Board of Regents of the University of Texas System, The Wistar Institute of Anatomy and BiologyInventors: Jerry SHAY, Gao ZHANG
-
Patent number: 10981867Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.Type: GrantFiled: September 16, 2019Date of Patent: April 20, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
-
Patent number: 10953108Abstract: The invention includes compositions and methods of generating a chimpanzee-derived adenovirus AdC6 or AdC7 vector vaccine comprising a deletion of E1, a deletion of E3 ORF3, ORF4, ORF5, ORF6, and ORF7 and a sequence encoding HIV protein gp140, gp160 or Gag, methods of treating and/or preventing or immunizing against HIV and methods of inducing an effector T cell, memory T cell and B cell immune response in a mammal administered the composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a mammal as well as a protein expression system.Type: GrantFiled: July 21, 2017Date of Patent: March 23, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Hildegund C. J. Ertl, Xiang Yang Zhou
-
Patent number: 10828363Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.Type: GrantFiled: September 15, 2017Date of Patent: November 10, 2020Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David Weiner, Megan Wise
-
Patent number: 10745761Abstract: The present invention relates to methods and systems for high risk screening, diagnosis, prognosis, and surveillance of lung cancer. Accordingly, in one aspect, the invention provides a method for diagnosing or evaluating whether a subject has, or is at risk of having, lung cancer such as NSCLS. The method comprises obtaining a first expression level of the AKAP4 gene of a population of cells from the blood of a test subject; and comparing the first expression level with a first predetermined reference value. A difference between the first expression level and first predetermined reference value correlates with a diagnosis or evaluation of a lung cancer.Type: GrantFiled: June 2, 2015Date of Patent: August 18, 2020Assignees: Valley Health System, The Wistar Institute of Anatomy and BiologyInventors: Kiranmai Gumireddy, Qihong Huang, Louise C. Showe, Ganepola A Ganepola
-
Patent number: 10640810Abstract: Provided herein are methods of detecting a target nucleic acid sequence. In one embodiment, the method includes contacting genomic DNA with a guide RNA having a portion complementary to the target sequence in the genomic DNA and with Cas9 nickase to produce a single-strand break in the genomic DNA at a specific location adjacent to the target sequence. The method further includes contacting the nicked DNA with a polymerase and fluorescently labeled nucleotide. The fluorescently labeled nucleotide is incorporated into the nicked DNA at the specific location and the target nucleic acid sequence is detected via fluorescent label.Type: GrantFiled: October 18, 2017Date of Patent: May 5, 2020Assignees: Drexel University, The Wistar Institute of Anatomy and Biology, Temple UniversityInventors: Ming Xiao, Harold C. Riethman, Wenhui Hu, Jennifer McCaffrey